Press release
Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021;
About this update from Insmed Incorporated
[{"type":"text","content":"--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--\n --Enrollment Timelines Provided for Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)--\n --Planning to Advance Brensocatib in Two Additional Potential Indications: Chronic Rhinosinusitis without Nasal Polyps (CRS) and Hidradenitis Suppurativa (HS)--\n --Cash Runway into 2024 to Support Company's Ongoing Programs--\n\n\nBRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's business and pipeline.\n\"Insmed made tremendous progress across our four pillars throughout 2021, and we begin 2022 from a position of strength, with seven ongoing clinical trials, commercial operations in three major territories, a pathway to ARIKAYCE growth, and a highly innovative research engine to identify what we believe to be the most promising next set of candidates,\" commented Will Lewis, Chair and Chief Executive Officer of Insmed. \"Importantly, our strong cash position will support advancement across our programs as we continue to lay the groundwork for what we believe will be a meaningful inflection point for the Company. I am enormously proud of our world-class team and what we have been able to achieve on behalf of patients with serious and rare diseases.\"\nRecent Corporate Developments & Program Highlights \nARIKAYCE \nInsmed launched ARIKAYCE in Japan in July of 2021, and early launch progress has been strong, with several positive trends. In Europe, ARIKAYCE has now been launched in Germany, the Netherlands, Wales, and Scotland. The Company is pursuing country-by-country reimbursement and launches throughout Europe, with a near-term focus on Italy, France, and England. Insmed continues to advance the post-marketing confirmatory frontline clinical trial program of ARIKAYCE in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). The ARISE trial, an interventional st...